-
Abciximab, a
glycoprotein IIb/IIIa
receptor antagonist manufactured by
Janssen Biologics BV and
distributed by Eli
Lilly under the
trade name ReoPro,...
- a
class of
antiplatelet agents.
Several GpIIb/IIIa
inhibitors exist:
abciximab (abcixifiban) (ReoPro)
eptifibatide (Integrilin)
tirofiban (Aggrastat)...
- fibrinogen. The gpIIb/IIIa
receptor is a
target of
several drugs including abciximab, eptifibatide, and tirofiban. Once
platelets are activated,
granules secrete...
- (Persantine)
Glycoprotein IIB/IIIA
inhibitors (intravenous use only)
Abciximab (ReoPro)
Eptifibatide (Integrilin)
Tirofiban (Aggrastat) Irreversible...
- (INN)
abanoquil (INN)
abarelix (INN)
abatacept (USAN)
Abasol Abbokinase abciximab (INN)
abecarnil (INN)
Abecma abediterol (INN)
Abegrin Abelcet Abenol abexinostat...
-
Churchill Livingstone. pp. 241, for the
examples infliximab, basiliximab,
abciximab, daclizumab, palivusamab, gemtuzumab,
alemtuzumab and rituximab, and mechanism...
- GPIIb/IIIa that has
found broad acceptance after the
specific antibody abciximab and the non-peptide
tirofiban entered the
global market. Eptifibatide...
-
Developed the drug that is
recommended for all
cardiac angioplasties (
abciximab) 1974
Created the
first MRI
image of a
living organism Discovered the...
-
points to the
widely accepted pronunciation of any
given INN. For example,
abciximab is
predictably /æbˈsɪksɪmæb/,
because for INNs
ending in -ciximab, the...
- form-factor for
monoclonal antibodies designated for
therapeutic use. The Fab
abciximab,
which inhibits blood clotting,
works by
disabling glycoprotein IIb/IIIa...
